Glass House Brands
Glass House Brands' revenue fell 9.4% to $182 million in fiscal 2025. Its operating margin was −9.1%, down from 2.9% a year earlier. Free cash flow was −$16 million, against $18 million a year earlier. The diluted share count rose 8.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
What Glass House Brands does
Glass House Brands is a cannabis company that operates only in California. It grows cannabis in large greenhouses in Carpinteria and Camarillo, makes products at a plant in Lompoc, and sells them to wholesalers and to stores, including its own. It runs dispensaries under the Farmacy, Natural Healing Center and The Pottery names.
Most of its revenue comes from selling bulk cannabis flower and trim to wholesalers: 62.8% of 2025 revenue. Packaged consumer products sold wholesale made up 10.7% and its own stores 26.5%. It also has licensing deals in Nevada and Florida and manages other companies' stores in California.
Its flower is mostly grown with sunlight in greenhouses, using extra lights only to control when plants flower. At the end of 2025 its licensed growing area was about 1,708,000 square feet, and it produced 666,433 pounds of dried cannabis equivalent that year. It had 357 full-time employees. The company files its annual report in Canada and the US.
Its biggest risks, as it describes them
- Cannabis remains illegal under US federal law, even though California allows it.
- Limited access to banks in the US and Canada because of its cannabis business.
- Competition from the illegal cannabis market and from other licensed growers.
- Losing or failing to renew the state and local licenses it needs to operate.
- Loan covenants in its senior secured credit facility that limit how it can run the business.
Income statement
Glass House Brands lost money in fiscal 2025: a net loss of $30 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 54 | 14 | 32 | 37 | 23 |
| Debt incl. finance leases | 45 | 63 | 66 | 61 | 71 |
| Net debt (negative means net cash) | −9 | 49 | 34 | 24 | 47 |
| Net debt to EBITDA | — | — | — | 1.2x | — |
| Debt to equity | 0.2x | 0.4x | 0.7x | 0.5x | 0.9x |
| Interest coverage | −13.2x | −7.4x | −5.0x | 0.6x | −2.3x |
| Current ratio | 1.2x | 0.7x | 0.6x | 1.0x | 1.8x |
| Quick ratio | 1.1x | 0.5x | 0.5x | 0.8x | 1.1x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 7 of 9 | 3 of 9 |
| Rule of 40 | 96.3% | 33.9% | −18.1% |
| Altman Z'' | −3.37 | −1.05 | −1.45 |
| Accruals ratio | −37.1% | −9.1% | −13.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | 5 of 9 | 7 of 9 | 3 of 9 |
Compare
Put Glass House Brands side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Glass House Brands | FY25 | −9.4% | −9.1% | −8.6% | −10.0% | — | 3 | |
| Kamada | FY25 | 12.1% | 14.5% | 8.7% | — | — | — | Compare |
| Stoke Therapeutics | FY25 | 404.5% | −11.2% | 24.4% | — | — | — | Compare |
| Phathom Pharmaceuticals | FY25 | 216.9% | −91.4% | −95.4% | — | — | 4 | Compare |
| Rhythm Pharmaceuticals | FY25 | 45.8% | −101.2% | −61.5% | — | — | 6 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 48 | 63 | 85 | 161 | 201 | 182 |
| Revenue growth | — | 30.9% | 34.3% | 89.5% | 24.9% | −9.4% |
| Gross profit | 19 | 16 | 21 | 81 | 97 | 77 |
| Research and development | — | — | — | — | — | — |
| Operating income | −6 | −36 | −56 | −50 | 6 | −16 |
| Net income | −17 | −43 | −33 | −98 | 0 | −30 |
| Diluted EPS (US$) | −0.78 | −1.11 | −0.83 | −1.62 | −0.21 | −0.55 |
| Diluted shares (millions) | 21 | 40 | 64 | 72 | 75 | 82 |
| Cash flow | ||||||
| Cash from operations | −8 | −20 | −41 | 23 | 28 | 11 |
| Capital expenditure | 4 | 108 | 28 | 12 | 10 | 27 |
| Free cash flow | −12 | −129 | −69 | 11 | 18 | −16 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 3 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 9 | 13 | 8 | 13 | 13 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 4 | 54 | 14 | 32 | 37 | 23 |
| Debt incl. finance leases | 16 | 45 | 63 | 66 | 61 | 71 |
| Total assets | 70 | 288 | 351 | 304 | 310 | 319 |
| Total liabilities | 43 | 106 | 130 | 158 | 146 | 144 |
| Shareholders' equity | 26 | 182 | 169 | 90 | 116 | 74 |
| Margins and ratios | ||||||
| Gross margin | 38.8% | 25.0% | 24.4% | 50.3% | 48.5% | 42.3% |
| Operating margin | −12.4% | −57.2% | −66.4% | −30.8% | 2.9% | −9.1% |
| Net margin | −34.5% | −68.2% | −38.8% | −61.1% | 0.3% | −16.3% |
| Free cash flow margin | −23.9% | −203.8% | −80.8% | 6.8% | 9.0% | −8.6% |
| Rule of 40 (growth + FCF margin) | — | −172.8% | −46.5% | 96.3% | 33.9% | −18.1% |
| Return on capital | — | −27.3% | −22.9% | −23.0% | 2.2% | −10.0% |
| Return on equity | — | −41.4% | −18.8% | −76.0% | 0.5% | −31.2% |
| Return on assets | — | −24.1% | −10.3% | −30.0% | 0.2% | −9.4% |
| Net debt to EBITDA | — | — | — | — | 1.2x | — |